One death case report of grade Ⅳ checkpoint inhibitor pneumonitis induced by atezolizumab
Attillizumab is a humanized monoclonal anti-body.With its widespread clinical application,there are grow-ing reports of immune-related adverse events.Checkpoint inhibitor pneumonitis(CIP)induced by attilizumab is a rare life-threatening adverse event.It has never been reported in China.Here we described and analysis an onset of CIP in a renal cancer patient after a 5-month therapy of attilizumab to enhance clinicians'understanding of its adverse effects.
checkpoint inhibitor pneumonitisimmune-associated pneumoniaatezolizumabrenal canceradverse drug reaction
NETL
NSTL
万方数据
